ask="1.6500"
ask_size="1000"
average_daily_volume="330753"
bid="1.5100"
bid_size="2000"
book_value="0.3390"
change="+0.0099"
change_from_200_day_moving_average="-0.1031"
change_from_50_day_moving_average="-0.0369"
change_from_52_week_high="-3.5101"
change_From_52_week_low="0.4799"
change_in_percent="+0.6266%"
close="1.5899"
dividend_pay_date="N/A"
dividend_per_share="N/A"
dividend_yield="N/A"
earnings_per_share="-1.4870"
ebitda="-12.32M"
eps_estimate_current_year="-1.5800"
eps_estimate_next_quarter="-0.3600"
eps_estimate_next_year="-0.8800"
ex_dividend_date="N/A"
float_shares="3761000"
high="1.6500"
high_52_weeks="5.1000"
last_trade_date="2/8/2017"
last_trade_price="1.5899"
last_trade_size="100"
last_trade_time="3:59pm"
low="1.5300"
low_52_weeks="1.1100"
market_capitalization="15.24M"
moving_average_200_day="1.6930"
moving_average_50_day="1.6269"
name="Eyegate Pharmaceuticals
Inc."
notes="N/A"
one_year_target_price="10.0000"
open="1.6500"
pe_ratio="N/A"
peg_ratio="0.0000"
percent_change_from_200_day_moving_average="-6.0887%"
percent_change_from_50_day_moving_average="-2.2713%"
percent_change_from_52_week_high="-68.8255%"
percent_change_from_52_week_low="+43.2342%"
previous_close="1.5800"
price_eps_estimate_current_year="N/A"
price_eps_Estimate_next_year="N/A"
price_per_book="4.6608"
price_per_sales="29.7595"
revenue="508889.00"
shares_outstanding="9585000"
short_ratio="2.3200"
stock_exchange="NCM"
symbol="EYEG"
volume="75549"
weeks_range_52="1.1100 - 5.1000"
